Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
![](/fileadmin/_processed_/a/7/csm_press-primrose-0324_531f92af1a.jpg)
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
![](/fileadmin/_processed_/9/9/csm_press-Avacc10-0324_7afcdc4fae.jpg)
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
![](/fileadmin/_processed_/9/7/csm_paul-news_f03d62b06d.jpg)
We interviewed Paul, our new Director QA/QC & EHS to learn about his career and his passion for quality.
![](/fileadmin/_processed_/2/3/csm_CARB-X_18a889ad18.jpg)
Intravacc secures $633K funding from CARB-X to develop a vaccine against Neisseria gonorrhoeae.
![](/fileadmin/_processed_/7/c/csm_First-Dutch-Innovations-FDI__c6556d1e58.png)
On the third of May last year the Ministry of Health, Welfare, and Sport (VWS) announced the sale of Intravacc B.V. and on December 28, 2023 VWS…
![](/fileadmin/_processed_/7/b/csm_New_website_2-1_412485ae56.jpg)
We are thrilled to announce the launch of our new website!
![](/fileadmin/_processed_/e/f/csm_jan-news_a63269d272.jpg)
Interview with Intravacc’s CEO dr. Jan Groen “Some milestones are measured by reliability”
![inVitro 01 inVitro 01](/fileadmin/_processed_/a/d/csm_inVitro-01_3fc0648481.jpg)
In vitro alternative assay to the replace rabbit pyrogen test for vaccines.
![](/fileadmin/_processed_/e/2/csm_press-9_b37966bc1b.jpg)
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
![](/fileadmin/_processed_/9/6/csm_Partner-Chonquing-Zhifei_b70408fbba.jpg)
Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products